Treatment of juvenile rheumatoid arthritis [PDF]
Korean Journal of Pediatrics, 2010 The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be ...
Kwang Nam Kim
doaj +1 more source
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]
, 2019 Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro +5 more
core +3 more sources
Arthritis Research & Therapy, 2022 Background There is limited information regarding disease-modifying antirheumatic drug (DMARD)-dependent risks of overall, incident, and recurrent herpes zoster (HZ) during first-line biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD ...
Seogsong Jeong +5 more
doaj +1 more source
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. [PDF]
, 2009 ObjectiveC-reactive protein (CRP) levels>3 mg/L and>10 mg/L are associated with high and very high cardiovascular risk, respectively, in the general population.
Graf, Jonathan +3 more
core +4 more sources
Современная ревматология, 2022 The review is devoted to the relationship between the pathogenetic mechanisms of coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases (IRD).
K. S. Rutskaya-Moroshan +2 more
doaj +1 more source
Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. [PDF]
, 2014 BackgroundIndividuals with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease, partly due to systemic inflammation and endothelial dysfunction.
Del Puerto, Gus +10 more
core +2 more sources
Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
RMD Open, 2021 We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk ...
Ronald F van Vollenhoven +3 more
doaj +1 more source
Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing [PDF]
, 2020 Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing.
Brinkman, Antonia Clara Katharina +10 more
core +1 more source
Repeat prescribing of medications: a system-centred risk management model for primary care organisations [PDF]
, 2017 Rationale, aims and objectives: Reducing preventable harm from repeat medication prescriptions is a patient safety priority worldwide. In the United Kingdom, repeat prescriptions items issued has doubled in the last 20 years from 5.8 to 13.3 items ...
Bartlett, Stephen +5 more
core +1 more source
Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study [PDF]
, 2017 [Abstract] The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an ...
Alegre-Sancho, Juan J. +11 more
core +2 more sources